Polymerase chain reaction assays for monitoring antiviral therapy and making therapeutic decisions in the treatment of acquired immunodeficiency syndrome
AssigneeLeland Stanford Junior University
InventorsMichael J. Kozal, Thomas C. Merigan
Life of this patent
Estimating the term…
Abstract
The present invention relates to methods of monitoring, via polymerase chain reaction, the clinical progression of human immunodeficiency virus infection and its response to antiretroviral therapy. According to the invention, polymerase chain reaction assays may be used to predict immunological decline and to identify, at an early stage, patients whose infection has become resistant to a particular antiretroviral drug regimen.
Claims45
A method of evaluating the effectiveness of antiretroviral therapy of an HIV-infected patient comprising:
- (i) collecting a plasma sample from an HIV-infected patient;
- and
- (ii) determining whether the plasma sample comprises nucleic acid encoding HIV reverse transcriptase having a mutation at codons codon 215 or 74, or codons 215 and 74 , in which the presence of the mutations mutation correlates positively with an accelerated immunologic decline of said patient compared to patients who do not have the mutations mutation.
A method of evaluating the effectiveness of antiretroviral therapy of an HIV-infected patient comprising:
- (i) collecting PBMC from an HIV-infected patient;
- and
- (ii) determining whether the PBMC comprise proviral HIV DNA which comprises a mutation at codons 74 or codon 215, or codons 215 and 74, of the HIV reverse transcriptase gene, in which the presence of the mutations mutation correlates positively with an accelerated immunologic decline of said patient compared with patients who do not have the mutations mutation.
A method of evaluating the effectiveness of antiretroviral therapy of an HIV-infected patient comprising:
- (i) collecting a plasma sample from an HIV-infected patient;
- and
- (ii) determining whether the plasma sample comprises nucleic acid encoding HIV reverse transcriptase having a mutation at codon 74, in which the presence of the mutation correlates positively with an accelerated immunologic decline of said patient compared to patients who do not have the mutation.
A method of evaluating the effectiveness of antiretroviral therapy of an HIV-infected patient comprising:
- (i) collecting a plasma sample from an HIV-infected patient;
- and
- (ii) determining whether the plasma sample comprises nucleic acid encoding HIV reverse transcriptase having a mutation at codons 215 and 74, in which the presence of the mutation correlates positively with an accelerated immunologic decline of said patient compared to patients who do not have the mutation.
A method of evaluating the effectiveness of antiretroviral therapy of an HIV-infected patient comprising:
- (i) collecting PBMC from an HIV-infected patient;
- and
- (ii) determining whether the PBMC comprise proviral HIV DNA which comprises a mutation at codon 74 of the HIV reverse transcriptase gene, in which the presence of the mutation correlates positively with an accelerated immunologic decline of said patient compared with patients who do not have the mutation.
A method of evaluating the effectiveness of antiretroviral therapy of an HIV-infected patient comprising:
- (i) collecting PBMC from an HIV-infected patient;
- and
- (ii) determining whether the PBMC comprise proviral HIV DNA which comprises a mutation at codons 215 and 74, of the HIV reverse transcriptase gene, in which the presence of the mutation correlates positively with an accelerated immunologic decline of said patient compared with patients who do not have the mutation.
Dependencies are inferred from the claim text.